[Epidural and intraventricular morphine therapy in the treatment of cancer pain].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to F Rychlicki.
Explore the source record for details and available documents.
Fifteen selected patients with advanced intrathoracic non-small cell lung cancer and solitary metastasis were treated by a combined program including craniotomy, brain and chest irradiation, and systemic chemotherapy. One patient died because of cerebral hemorrhage after the operation. Five patients failed to achieve neurologic benefit. Nine patients improved their neurologic grading, and the median duration of improvement was 10 months (range, 1-26 months). The responses to systemic treatment were: one complete response, three partial responses, six stable disease responses, and four progressive disease responses. The overall median survival was 6 months from craniotomy and 12 months from diagnosis. Five patients became long survivors; they had a survival time ranging between 12 and 26 months after craniotomy. In conclusion, one third of patients had a satisfactory response to treatment; this outlines the value of the combined aggressive therapeutic approach also performed in patients who had a highly unfavorable prognoses.
Explore the source record for details and available documents.
The aim of this study is to describe the authors' experience with intra-arterial ACNU chemotherapy of malignant gliomas. The prognosis of cerebral malignant gliomas remains poor, whatever traditional therapy is applied. ACNU is a well tolerated nitrosourea with a strong antimitotic effect on neurogenic cells both in vitro and in vivo; this drug has enhanced efficacy when used at high concentrations, particularly as an intraarterial infusion. Seventy-six patients have been studied to date, 68 of whom are evaluable; these patients were treated by intra-arterial infusion of ACNU (100 mg/m2) every 6 weeks, with a mean of 2.5 courses per patient. The objective response (OR) was 28% and analysis of pretreatment factors revealed that survival was influenced by histological grade, other types of therapy applied, and age. In general IAC is well tolerated and the response and survival appear to be better than with systemic chemotherapy.
Nineteen out of 31 cases of well-differentiated oligodendrogliomas were selected on the basis of clinical and morphological parameters. The patients were divided into 3 groups according to the length of the survival period. In each case 8 clinical, 4 morphological and 3 morphometrical parameters were scored. The quantitative analysis of nuclei of oligodendroglioma cells, performed by means of an automated microscopic picture analyzer (Leitz-TAS), allowed the nuclear area, perimeter and roundness factor of 200 nuclei to be calculated for each case. Twenty-eight additional features were derived from the data obtained. The descriptive statistical analysis, based on Student's t-test and Chi-square test showed significant differences (p less than 0.05) with regard to the SD of the 10 largest values of the nuclear perimeter among the derived quantitative parameters. Among the clinical parameters, the increased intracranial pressure as a late complication was also significant. Multivariate analysis, based on Bayes theorem, allowed 89% of the cases to be allocated to the actual groups by means of 6 clinical parameters, 57% by means of 4 morphological parameters and 100% by means of a set of 3 morphometrical parameters. The morphometric data proved to be better discriminants than clinical and subjectively evaluated morphological parameters in low grade oligodendrogliomas.